6THOMAS F, LUSCHER M B. Endothelins and endothelin receptor antagonists : therapeutic considerations for a novel class of cardiovascular drugs[J]. Circulatlon,2000 ,102 :243.
7HIRATA Y, EMORI T, EGUCHI S. Endothelin receptor subtype Bmediates synthesis of nitric oxide by cultured bovine endothelial cells [J]. J Clin Invest, 1993, 91 : 1367 -1373.
8MASAKI T. Possible role of endothelin in endothelial regulation of va-scular tone [ J ]. Ann Rev Pharmacol Toxicol, 1995, 35:235 - 255.
9ROUX S, BREU V, ERTEL S I, et al. Endothelin antagonism with bosentan: a review of potential applications [ J ]. J Mol Med, 1999, 77(4) :364 -376.
3[1]Phillips MI. Gene therapy for hypertension: the preclinical data [J]. Hypertension, 200i, 38(3 pt 2):543-548.
4[2]Chao J, Chao L. Kallikrein gene therapy: a new strategy for hypertensive diseases [J]. Immunopharmacology, 1997,36: 229-236.
5[3]Wolf Wc, Yoshida H, Agata J, et al. Humen tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardioac remodeling in chronic renal failure[J]. Kidney Int,2000,58:730-739.
6[4]Chao J, Jim L, Lin KF, et al. Adrenomedulin gene delivery reduces blood pressure in spontaneously hypertensive rats [J].Hypertens Res, 1997, 20:2692-2697.
7[5]Dobrzynski E, Yoshida H, Chao J, et al. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats[J]. Immunopharmacology, 1999, 44:57-65.
8[6]Lin KF, Chao L, Chao J. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats [J]. Hum Gene Ther, 1998,9: 1429-1438.
9[7]Sellers KW, Katovich MJ, Gelband CH, et al. Gene tharapy to control hypertension: current studies and future perspectives [J]. Am J Med Sci, 2001, 322 (1):1-6.
10[8]Jeunemaitre Ⅹ, Soubrier F, Kotelevetsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen[J]. Cell,1992,71:169-180.
